Biota parasitária gastrointestinal de caititus "Tayassu tajacu Linnaeus 1758" (Pecari tajacu Jacq.) criados em cativeiro.

Os caititus foram identificados como uma das espécies mais caçadas na região da Transamazônica ? PA. (BONAUDO et al., 2002). Nas regiões de colonização da Amazônia, encontram-se várias espécies silvestres cuja única exploração baseia-se na caça que é uma fonte de proteína alternativa para a população local. Esta, junto com o desmatamento, a fragmentação de habitats e o comércio ilegal pode causar a diminuição de espécies. Uma alternativa para solucionar este problema é o incentivo à criatórios, que são uma forma de utilização sustentável da biodiversidade, geração de renda e identificação das ações conservacionistas (MMA, 2001). Objetivou-se no presente trabalho estudar a biota parasitária gastrintestinal presente em caititus criados em cativeiro em 2 criatórios no Estado do Pará, um na Embrapa Amazônia Oriental, Belém-PA e outro em criatório de produtor comercial em Santa Izabel ? PA, por ser o fator sanitário mais importante desta espécie em cativeiro e afim de disponibilizar dados mais atuais literatura sobre os animais em questão. Para as análises de endoparasitas gastrintestinais foram realizadas análises de fezes com os seguintes métodos: Sedimentação e Mcmaster. A ocorrência de parasitas gastrintestinais até o presente momento é de 71,92% (41 animais), sendo que destes 85,36% (35 animais) apresentaram infecção simples e 14,63% (6 animais) apresentaram infecção múltipla. Os parasitas identificados e suas respectivas incidências foram Balantidium coli (64,91%); Ascaris suun (8,77%)e grupo dos Strongylideos (8,77%)

Uso de anti-helmínticos e bioestimulantes no desempenho de bovinos de corte suplementados a pasto no estado do Pará.

O experimento avaliou o efeito da vermifugação e da utilização de bioestimulantes no ganho de peso e no escore de condição corporal (ECC) de bovinos de corte, criados em sistema de pastejo rotacionado com suplementação a pasto, no Estado do Pará, durante 160 dias. Foram utilizados 132 bovinos machos não castrados, com idade média de 24 meses, da raça Nelore (Bos taurus indicus). Os grupos experimentais compreenderam o grupo G1 (controle; n=33), G2 (moxidectina 1%; n=33), G3 (moxidectina 10%; n=33) e G4 (ivermectina 3,15%; n=33). Em todos os grupos foram estabelecidas três subparcelas, a fim de serem testados dois bioestimulantes de crescimento animal (bioestimulante 1 e bioestimulante 2). Não houve diferença estatística significativa no ganho de peso médio, no ECC e nas contagens de OPG entre animais do G1, G2, G3 e G4, independentemente dos anti-helmínticos e/ou bioestimulantes usados. Contudo, o tratamento baseado na associação de moxidectina 1% e o bioestimulante 2 apresentou maior receita líquida e incrementou a lucratividade da terminação em 1,24%. Os resultados sugerem que não há necessidade de um controle contra nematódeos durante a terminação, desde que os animais apresentem uma baixa carga parasitária, porém o uso de fármacos pode, sob certas condições, apresentar resultado econômico favorável

LICIACube Mission: The Fastest Fly-By Ever Done by a CubeSat

As SmallSats are gathering an ever-increasing importance for all types of space missions, they are asked more often to operate in harshest environments and to complete the most complex tasks. One of these demanding technical challenges arises in the frame of the planetary defense. Space missions towards asteroids have garnered the due attention in recent years and, in this regard, NASA has developed the Double Asteroid Redirection Test (DART) mission, in which the Italy will lend its contribution. While DART acts as a kinetic impactor deflecting the orbit of the asteroid Dimorphos, the moon of the targeted binary system Didymos, the Light Italian CubeSat for Imaging of Asteroid (LICIACube) collects and gathers valuable images of the effect of the DART impact on the rocky body. LICIACube will allow to study the structure and evolution of the ejecta plume resulting from the impact, and to model both impacted and non-impacted sides of Dimorphos. LICIACube is an Italian Space Agency (ASI) project, whose design, integration and testing have been assigned to the aerospace company Argotec. The scientific team is enriched by University of Bologna team, supporting the orbit determination and the satellite navigation, Polytechnic of Milan, for mission analysis support and optimization and INAF (National Institute of Astrophysics), which provides support in the scientific operations of the satellite, instrument calibrations and data exploitation. This work focuses on the fly-by of LICIACube which will be accomplished using the imaging capabilities provided by theArgotecHAWK-6 platform and by the autonomous navigation system. In order to acquire high-resolution images, LICIACube approaches Dimorphos at a relative distance of 55km. The very close fly-by, the high relative velocity of ∼7 km/s with respect to the asteroid and the need to keep LICIACube camera pointed at Dimorphos make the mission very challenging. In addition, since the binary asteroid system is ∼10 million kilometers away from Earth, the fly-by has to be performed with no real time commanding. As a result, LICIACube shall be able to autonomously analyze all information from its sensors to track the asteroid. The evaluation and subsequent solutions to this problem are presented in this paper, as well as a unit-level description of the parts included in the autonomous navigation system. Finally, an overview of the verification of both unit-level and system-level strategies is outlined

Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA trial

Purpose: this study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer. Patients and methods: mean progression-free survival (PFS) was estimated for niraparib and RS by fitting parametric survival distributions to Kaplan-Meier data for 553 patients with recurrent ovarian cancer who were enrolled in the phase III ENGOT-OV16/NOVA trial. Patients were categorized according to the presence or absence of a germline BRCA mutation-gBRCAmut and non-gBRCAmut cohorts. Mean time with toxicity was estimated based on the area under the Kaplan-Meier curve for symptomatic grade 2 or greater fatigue, nausea, and vomiting adverse events (AEs). Time with toxicity was the number of days a patient experienced an AE post-random assignment and before disease progression. TWiST was estimated as the difference between mean PFS and time with toxicity. Uncertainty was explored using alternative PFS estimates and considering all symptomatic grade 2 or greater AEs. Results: in the gBRCAmut and non-gBRCAmut cohorts, niraparib treatment resulted in a mean PFS benefit of 3.23 years and 1.44 years, respectively, and a mean time with toxicity of 0.28 years and 0.10 years, respectively, compared with RS. Hence, niraparib treatment resulted in a mean TWiST benefit of 2.95 years and 1.34 years, respectively, compared with RS, which is equivalent to more than four-fold and two-fold increases in mean TWiST between niraparib and RS in the gBRCAmut and non-gBRCAmut cohorts, respectively. This TWiST benefit was consistent across all sensitivity analyses, including modeling PFS over 5-, 10-, and 15-year time horizons. Conclusion: patients who were treated with niraparib compared with RS experienced increased mean TWiST. Thus, patients who were treated with niraparib in the ENGOT-OV16/NOVA trial experienced more time without symptoms or symptomatic toxicities compared with control

How does study quality affect the results of a diagnostic meta-analysis?

Background: The use of systematic literature review to inform evidence based practice in diagnostics is rapidly expanding. Although the primary diagnostic literature is extensive, studies are often of low methodological quality or poorly reported. There has been no rigorously evaluated, evidence based tool to assess the methodological quality of diagnostic studies. The primary objective of this study was to determine the extent to which variations in the quality of primary studies impact the results of a diagnostic meta-analysis and whether this differs with diagnostic test type. A secondary objective was to contribute to the evaluation of QUADAS, an evidence-based tool for the assessment of quality in diagnostic accuracy studies. Methods: This study was conducted as part of large systematic review of tests used in the diagnosis and further investigation of urinary tract infection (UTI) in children. All studies included in this review were assessed using QUADAS, an evidence-based tool for the assessment of quality in systematic reviews of diagnostic accuracy studies. The impact of individual components of QUADAS on a summary measure of diagnostic accuracy was investigated using regression analysis. The review divided the diagnosis and further investigation of UTI into the following three clinical stages: diagnosis of UTI, localisation of infection, and further investigation of the UTI. Each stage used different types of diagnostic test, which were considered to involve different quality concerns. Results: Many of the studies included in our review were poorly reported. The proportion of QUADAS items fulfilled was similar for studies in different sections of the review. However, as might be expected, the individual items fulfilled differed between the three clinical stages. Regression analysis found that different items showed a strong association with test performance for the different tests evaluated. These differences were observed both within and between the three clinical stages assessed by the review. The results of regression analyses were also affected by whether or not a weighting (by sample size) was applied. Our analysis was severely limited by the completeness of reporting and the differences between the index tests evaluated and the reference standards used to confirm diagnoses in the primary studies. Few tests were evaluated by sufficient studies to allow meaningful use of meta-analytic pooling and investigation of heterogeneity. This meant that further analysis to investigate heterogeneity could only be undertaken using a subset of studies, and that the findings are open to various interpretations. Conclusion: Further work is needed to investigate the influence of methodological quality on the results of diagnostic meta-analyses. Large data sets of well-reported primary studies are needed to address this question. Without significant improvements in the completeness of reporting of primary studies, progress in this area will be limited

Geographic Variations in Retention in Care among HIV-Infected Adults in the United States

ObjectiveTo understand geographic variations in clinical retention, a central component of the HIV care continuum and key to improving individual- and population-level HIV outcomes.DesignWe evaluated retention by US region in a retrospective observational study.MethodsAdults receiving care from 2000–2010 in 12 clinical cohorts of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) contributed data. Individuals were assigned to Centers for Disease Control and Prevention (CDC)-defined regions by residential data (10 cohorts) and clinic location as proxy (2 cohorts). Retention was ≥2 primary HIV outpatient visits within a calendar year, >90 days apart. Trends and regional differences were analyzed using modified Poisson regression with clustering, adjusting for time in care, age, sex, race/ethnicity, and HIV risk, and stratified by baseline CD4+ count.ResultsAmong 78,993 adults with 444,212 person-years of follow-up, median time in care was 7 years (Interquartile Range: 4–9). Retention increased from 2000 to 2010: from 73% (5,000/6,875) to 85% (7,189/8,462) in the Northeast, 75% (1,778/2,356) to 87% (1,630/1,880) in the Midwest, 68% (8,451/12,417) to 80% (9,892/12,304) in the South, and 68% (5,147/7,520) to 72% (6,401/8,895) in the West. In adjusted analyses, retention improved over time in all regions (p<0.01, trend), although the average percent retained lagged in the West and South vs. the Northeast (p<0.01).ConclusionsIn our population, retention improved, though regional differences persisted even after adjusting for demographic and HIV risk factors. These data demonstrate regional differences in the US which may affect patient care, despite national care recommendations

CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?

We assessed CD4 count at initial presentation for HIV care among ≥50-year-olds from 1997-2007 in 13 US and Canadian clinical cohorts and compared to <50-year-olds. 44,491 HIV-infected individuals in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) were included in our study. Trends in mean CD4 count (measured as cells/mm3) and 95% confidence intervals ([,]) were determined using linear regression stratified by age category and adjusted for gender, race/ethnicity, HIV transmission risk and cohort. From 1997-2007, the proportion of individuals presenting for HIV care who were ≥50-years-old increased from 17% to 27% (p-value < 0.01). The median CD4 count among ≥50 year-olds was consistently lower than younger adults. The interaction of age group and calendar year was significant (p-value <0.01) with both age groups experiencing modest annual improvements over time (< 50-year-olds: 5 [4 , 6] cells/mm3; ≥50-year-olds: 7 [5 , 9] cells/mm3), after adjusting for sex, race/ethnicity, HIV transmission risk group and cohort; however, increases in the two groups were similar after 2000. A greater proportion of older individuals had an AIDS-defining diagnosis at, or within three months prior to, first presentation for HIV care compared to younger individuals (13% vs. 10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed